Onkologie - spezialisierte Tumortherapie

Peritonealkarzinose - Bauchfellkarzinose - Bauchfellkrebs
chirurgische Onkologie - regionale Chemotherapie - Peritonektomie

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

from The Lancet, Volume 359, Number 9319 18 May 2002

Medical Research Council Oesophageal Cancer Working Party*
*Members and collaborators listed at end of report
Correspondence to: Dr D J Girling, MRC Clinical Trials Unit, Cancer Division, 222 Euston Road, London NW1 2DA, UK (e-mail:Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!)

Background
The outlook for patients with oesophageal cancer undergoing surgical resection with curative intent is poor. We aimed to assess the effects of preoperative chemotherapy on survival, dysphagia, and performance status in this group of patients.

Methods
802 previously untreated patients with resectable oesophageal cancer of any cell type were randomly allocated either two 4-day cycles, 3 weeks apart, of cisplatin 80 mg/m2by infusion over 4 h plus fluorouracil 1000 mg/m2daily by continuous infusion for 4 days followed by surgical resection (CS group, n=400), or resection alone (S group, 402). Clinicians could choose to give preoperative radiotherapy to all their patients irrespective of randomisation. Primary outcome measure was survival time. Analysis was by intention to treat. Findings
No patients dropped out of the study. Resection was microscopically complete in 233 (60%) of 390 assessable CS patients and 215 (54%) of 397 S patients (p<0·0001). Postoperative complications were reported in 146 (41%) CS and 161 (42%) S patients. Overall survival was better in the CS group (hazard ratio 0·79; 95% CI 0·67-0·93; p=0·004). Median survival was 512 days (16·8 months) in the CS group compared with 405 days (13·3 months) in the S group (difference 107 days; 95% CI 30-196), and 2-year survival rates were 43% and 34% (difference 9%; 3-14).

Interpretation
Two cycles of preoperative cisplatin and fluorouracil improve survival without additional serious adverse events in the treatment of patients with resectable oesophageal cancer. Lancet2002;359:1727-33

Weiterlesen: http://www.ncbi.nlm.nih.gov/pubmed/12049861

Sollten Sie Fragen zu Inhalten dieser Webseite haben oder als Betroffener weitere Informationen benötigen, können Sie gerne mit uns in Kontakt treten. Zur korrekten, unentgeltlichen Beantwortung Ihrer Anfragen werden alle aktuellen Unterlagen, wie Laborbefunde, OP-Berichte und CT- oder MR-Bilder benötigt.
Für die Übermittlung Ihrer Anfrage steht Ihnen das Kontaktformular zur Verfügung

Dr. med. Herwart Müller

Chefarzt der Abteilung für Allgemeinchirurgie in Wertheim
Rotkreuzklinik Wertheim
E-Mail: Herwart.Mueller@swmbrk.de
Sekretariat: Frau Anneliese Holzhäuser, Frau Birgit Rauer
E-Mail: anneliese.holzhaeuser@swmbrk.de
birgit.rauer@swmbrk.de
Telefon: 09342/303-5002
Fax:         09342/303-5001
Empfang: 09342/303-0
Rotkreuzklinik Wertheim gGmbH, Rotkreuzstr. 2
97877 Wertheim

Rotkreuzklinik Wertheim gGmbH

Abteilung für Allgemeinchirurgie
Rotkreuzstr. 2
97877 Wertheim / Bayern
Telefon:
+49 9342 / 303-5002

Sprechstunde

Zur Vorstellung in der Sprechstunde werden alle aktuellen Unterlagen, wie Laborbefunde, OP-Berichte und CT- oder MR-Bilder benötigt